Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
189
-
Total 13F shares, excl. options
-
80.8M
-
Shares change
-
+2.07M
-
Total reported value, excl. options
-
$369M
-
Value change
-
+$7.86M
-
Put/Call ratio
-
0.32
-
Number of buys
-
93
-
Number of sells
-
-77
-
Price
-
$4.57
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q1 2025
212 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 189 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80.8M shares
of 89.6M outstanding shares and own 90.15% of the company stock.
Largest 10 shareholders include Alphabet Inc. (12.3M shares), BlackRock, Inc. (7.88M shares), BVF INC/IL (6.9M shares), Casdin Capital, LLC (4M shares), VANGUARD GROUP INC (3.96M shares), STATE STREET CORP (3.09M shares), Novo Holdings A/S (3M shares), Schonfeld Strategic Advisors LLC (2.92M shares), Woodline Partners LP (2.77M shares), and T. Rowe Price Investment Management, Inc. (2.49M shares).
This table shows the top 189 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.